Fresenius Medical Care

• Homepage
• To our Shareholders
• Business segments
• Fresenius Medical Care

• Contact

  Fresenius SE & Co. KGaA
  Investor Relations & Sustainability
  +49 (0) 6172 608-2485
  ir-fre@fresenius.com

• Related Links

  • Last year's report
  • Fresenius Medical Care Website
  • Glossary
  • Downloads
  • Personal Data Request

• Share price

  FRESENIUS SE & CO. KGaA

   

   

   

  Data is delayed by 15 minutes.

  Detailed chart

• Library

  • Annual Report 2020 (PDF, 10 MB)
  • Factsheet FY/20 (PDF, 452 KB)

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases. We aim to create a future worth living for chronically and critically ill patients – worldwide and every day.

Highlights 2020

Fresenius Medical Care expands production at St. Wendel plant in response to higher demand caused by COVID-19 pandemic

Work on the new line was accelerated due to the coronavirus pandemic, enabling the company to put it into operation several months ahead of schedule. Severe COVID-19 cases often cause acute kidney failure, which has significantly increased worldwide demand for the solutions needed to conduct acute dialysis

Fresenius Medical Care partners with other dialysis providers to combat COVID-19 pandemic in the United States

The goal was to create a nationwide emergency plan with other dialysis organizations in order to create capacities across providers for isolated treatment and thus ensure the continuity of care for dialysis patients.

FDA FDA (U.S. Food & Drug Administration)Official authority for food observation and drug registration in the United States. clears Novalung for treatment of acute respiratory and cardiopulmonary failure

The Novalung ECMO system (“extracorporeal membrane oxygenation”) maintains the patient’s blood circulation and oxygenates their blood, reducing the stress on damaged heart and lungs. Novalung is the first ECMO system to be cleared for more than six hours of use as extracorporeal life support.

Comprehensive dialysisDialysisForm of renal replacement therapy where a semipermeable membrane – in peritoneal dialysis the peritoneum of the patient, in hemo­dialysis the membrane of the dialyzer – is used to clean a patient’s blood. products and services

When the kidney function of patients fails, dialysis takes over the vital task of cleansing the blood of toxins and surplus water. We offer products and services along the entire dialysis value chain. In addition to dialysis machines, dialyzers, and related disposables, we operate our own dialysis clinics worldwide. As part of our strategy 2025, we will concentrate on three key areas in which we want to leverage our core competencies – innovation of products, operating outpatient facilities, standardizing medical procedures, and efficiently coordinating patients:

Renal care continuum

By applying digital technologies such as artificial intelligence, we work on new forms of renal therapy to foster personalized medicine and holistic home care, among other things. Our value-based care models will push forward the transition from fee-for-service to pay-for-performance models to offer even better and affordable care. We are expanding these models to the treatment of chronic kidney disease and the area of kidney transplantation. Also, we continue to invest in the development of renal care innovations and gain access to new technologies.

Critical care solutions

We are extending our critical care portfolio to other extracorporeal intensive care therapy areas, such as the treatment of heart, lung, and multi-organ failure.

Complementary assets

To create an additional basis for future growth, we are further expanding our network of complementary assets through partnerships, investments, and acquisitions. This will help us to create additional medical value while cutting costs.

Market dynamics

Sales and earnings development

Source:
~ 3% patient growth in 2020:
Source: own research Fresenius Medical Care

Growth of home hemodialysis treatments in 2020 in the United States: + 37 %
Source: own research Fresenius Medical Care

Global market for dialysis products and services ~ € 82 bn
Source: own research Fresenius Medical Care

Big Data is driving new treatment models ~ 54 m dialysis treatments in 2020
Source: own research Fresenius Medical Care

Quality in dialysis treatments enables saving in the U.S. market
Source: Kidney Care Partners: United States Renal
Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States.
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda,MD, 2018.